Clinical Insights: July 7, 2020

    Welcome to RxStrategies’ Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place. Contact us to learn more.

    New Drug Approval 

    ByfavoTM (remimazolam) Injection – New Drug Approval – July 2, 2020 – Cosmo Pharmaceuticals announced that the US Food and Drug Administration (FDA) has approved Byfavo™ (remimazolam injection) for the induction and maintenance of procedural sedation in adults undergoing procedures lasting 30 minutes or less. ByfavoTM is a very rapid onset/offset IV benzodiazepine sedative for use during invasive medical procedures lasting 30 minutes or less, such as colonoscopy and bronchoscopy. Approximately 25 million such procedures take place annually in the US, of which ~90% use moderate sedation. <Read More> 

    RukobiaTM (fostemsavir) Extended-Release Tablets – New Drug Approval – July 2, 2020 – The U.S. Food and Drug Administration approved RukobiaTM (fostemsavir), a new type of antiretroviral medication for adults living with HIV who have tried multiple HIV medications and whose HIV infection cannot be successfully treated with other therapies because of resistance, intolerance or safety considerations. <Read More> 

    DojolviTM (triheptanoin) Oral Liquid – New Drug Approval – June 30, 2020 – Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development and commercialization of novel products for rare and ultra-rare diseases, announced that the U.S. Food and Drug Administration (FDA) has approved Dojolvi™ (triheptanoin) as a source of calories and fatty acids for the treatment of pediatric and adult patients with molecularly confirmed long-chain fatty acid oxidation disorders (LC-FAOD). LC-FAOD are a group of rare, lifelong and life-threatening genetic disorders in which the body is unable to convert long-chain fatty acids into energy. <Read More> 

    PhesgoTM (pertuzumab, trastuzumab, and hyaluronidase-zzxf) Injection – New Drug Approval – June 29, 2020 – The U.S. Food and Drug Administration approved PhesgoTM – a combination of pertuzumab, trastuzumab and hyaluronidase–zzxf—for injection under the skin to treat adult patients with HER2-positive breast cancer that has spread to other parts of the body, and for treatment of adult patients with early HER2-positive breast cancer. Patients should be selected based on an FDA-approved companion diagnostic test. <Read More>

    New Formulation Approval

    No new update.

    New Indication Approval

    Keytruda® (pembrolizumab) Injection – New Expanded Indication – June 29, 2020 – The U.S. Food and Drug Administration approved Keytruda® (pembrolizumab) for intravenous injection for the first-line treatment of patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer. This marks the first immunotherapy approved for this patient population as a first-line treatment and which is administered to patients without also giving chemotherapy. <Read More>

    New Drug Shortage

    July 06, 2020

    July 02, 2020

    New Drug Recall and Safety Alerts

    Metformin Extended-Release Products by Granules Pharmaceuticals – New Drug Recall – July 6, 2020 – Granules Pharmaceuticals, Inc., Chantilly, VA is voluntarily recalling twelve (12) lots of Metformin Hydrochloride Extended-Release Tablets USP, 750 mg, 100 and 500 count bottles within expiry to the consumer level due to the detection of NNitrosodimethylamine (NDMA) levels above the Acceptable Daily Intake Limit. Granules’ test results showed NDMA levels above the FDA acceptable limit in one (1) out of the twelve (12) batches distributed to the US market. All other batches continue to remain within the specifications. Out of abundance of caution Granules Pharmaceuticals, Inc. has decided to voluntarily recall all twelve (12) of the distributed lots within expiry of Metformin Hydrochloride Extended-Release Tablets USP, 750 mg from the market. <Read More>

    New Generic Approval and Launch

    No new update.

    Clinical and Pharmacy News

    CIDP Care: A Patient and Clinical Experts Weigh In – July 6, 2020 – At a virtual panel discussion held in conjunction with the Asembia Specialty Pharmacy Summit, several experts covered chronic inflammatory demyelinating polyneuropathy (CIDP). Paul Mathew, MD, DNBPAS, FAAN, FAHS, served as moderator for this dynamic discussion, which incorporated clips of an interview highlighting a patient’s perspective on the effects of living with CIDP. These videos effectively demonstrated the patient’s journey from diagnosis to navigating the health care system throughout his treatment. <Read More> 

    New Guideline: Don’t Routinely Screen for EAC in Patients with Chronic GERD – July 6, 2020 – A new guideline from the Canadian Task Force on Preventive Health Care, based on a rigorous systematic review of the latest evidence, found no benefit of routine screening for esophageal adenocarcinoma (EAC) and precursor conditions (Barrett esophagus and dysplasia) in patients with chronic gastroesophageal reflux disease (GERD). <Read More> 

    Amgen Ruling Could Prevent Slowdowns in Biosimilar Market Entry – July 6, 2020 – Changes to a biosimilar’s manufacturing locations or labels won’t be enough for innovator biotech companies to block a competitor from bringing their drug to market following a Federal Circuit ruling in a case over an Amgen Inc. cancer drug. <Read More> 

    Can Early Screening Reduce Breast Cancer Mortality Among Childhood Cancer Survivors? – July 6, 2020 – In survivors of childhood cancer, early initiation of annual breast cancer screening with MRI, with or without mammography, may reduce breast cancer mortality by half or more, according to a study published in Annals of Internal Medicine. <Read More> 

    Gabapentinoids Ineffective for Pain Relief After Surgery – July 6, 2020 – Would you want to take Lyrica (pregabalin) for pain relief after a major surgery? What about Neurontin (gabapentin)? Both drugs belong to a class of nerve medication called gabapentinoids that are increasingly being prescribed to patients perioperatively (after surgery) as an alternative to opioid pain medication. But gabapentinoids also have risks and there is little evidence to support their use for postoperative pain relief, according to a large new study by a team of Canadian researchers.  “No clinically significant analgesic effect for the perioperative use of gabapentinoids was observed. <Read More> 

    A Guide to Managing Opioid Use Disorder for the Pediatric-Focused APRN – July 6, 2020 – There are many medication-based treatment options available for the management of neonatal abstinence syndrome and pediatric opioid use disorder, according to a session at the virtual National Association of Pediatric Nurse Practitioners 2020 Annual Meeting. There was a 268% increase in pediatric opioid mortality in the United States from 1999-2016, with 80% being unintentional deaths and 73% attributed to prescription opioids. In regard to the 1/3 of adolescents who died of co-ingestion, the most common co-ingestions are benzodiazepine and cocaine. <Read More> 

    Boosting Molecular Testing in Patients with GIST Would Have Minimal Cost Impact, Study Finds – July 6, 2020 – An increase in molecular testing of patients with gastrointestinal stromal tumors (GIST) would allow physicians to make better therapeutic decisions without a significant uptick in the cost of care, according to a new analysis. The research found that increasing molecular testing rates to 100% among patients with 2 mutation types would result in an overall cost increase of just $15,213 per million members of a managed care plan per year. That breaks down to just 1.5 cents per member, per year, wrote corresponding author David Proudman, M.P.H., of the Analysis Group economic consulting firm. <Read More> 

    Opioid Dispensing Guidelines: Pharmacists’ Role in Combating Epidemic – July 6, 2020 – Pennsylvania has been working on improving things as to the dispensing and the use of opioids for the treatment of pain for several years. Up until a few years ago, Pennsylvania was only one of a handful of states that did not have a functioning prescription drug monitoring program…While today most hospitals, physician groups and other health care providers focus on the ramifications of its doctors who overprescribe narcotics, there are equally severe repercussions for pharmacists who dispense these drugs directly to patients. Pharmacists provide care to patients in various settings, from community stores, to clinics, to hospitals. <Read More> 

    JAK Inhibitors Are Important Tools for Patients With Myelofibrosis – July 3, 2020 – In one virtual symposium held in conjunction with the Asembia Specialty Pharmacy Summit, speakers delved into the rare cancer myelofibrosis. This cancer is characterized by scar tissue accumulation in the bone marrow, which leads to an insufficient quantity of normal blood cells. This deficiency in normal cells eventually precipitates the signs and symptoms of primary myelofibrosis…The JAK inhibitors are currently a treatment cornerstone, having largely replaced traditional chemotherapy. Ruxolitinib is FDA approved for intermediate-risk or high-risk myelofibrosis, with the evidence for efficacy and safety coming from two phase 3 studies. Fedratinib is also FDA approved for intermediate- to high-risk primary or secondary myelofibrosis. Evidence for use of this medication came from the JAKARTA trial. <Read More> 

    NCCN Patient Guidelines Highlight Side Effects of Immunotherapy, CAR T-Cell Therapy – July 3, 2020 – While immunotherapy has become an important treatment option for some cancers, and it is often well tolerated, it can have different side effects than traditional approaches, such as chemotherapy. The National Comprehensive Cancer Network (NCCN) recently released a new set of guidelines to help patients and caregivers understand the unique and severe side effects of immune checkpoint inhibitors (ICIs), a common type of immunotherapy. <Read More> 

    The Treatment of Tics in Children with ADHD – July 3, 2020 – At the 2020 Virtual Conference on Pediatric Health Care, Dawn Garzon Maaks, PhD, CPNP-PC, PMHS, FAANP, FAAN, the immediate past president of the National Association of Pediatric Nurse Practitioners and the associate professor at the University of Portland in the School of Nursing, discussed important elements in the diagnosis and treatment of tics in children with attention deficit hyperactivity disorder (ADHD). <Read More> 

    Randall Discusses Testing and Treatment Choices for Ovarian Cancer – July 3, 2020 – Leslie M. Randall, MD, MAS, professor, Department of Obstetrics and Gynecology Division Director, Division of Gynecologic Oncology, Virginia Commonwealth University, discussed the treatment regimens available for an African American patient with ovarian cancer. <Read More> 

    EAN Guidelines For Management Of Medication-Overuse Headache – July 3, 2020 – The European Academy of Neurology has released guidelines for the management of patients with medication-overuse headache (MOH). The guidelines have been published in the European Journal of Neurology. The frequent use of medication to treat migraine attacks can lead to an increase in migraine frequency and is called medication‐overuse headache (MOH) which is very frequent. Therefore, the guidelines have been reported to meet the need for patient education, and multidisciplinary specialists including neurologists, pain specialists, and behavioral psychologists working together to treat patients with MOH. <Read More>

    Updated ESMO Prostate Cancer Guidelines Released – July 3, 2020 – ESMO has issued updated Clinical Practice Guidelines on prostate cancer covering all aspects of diagnosis, treatment, and follow-up. The guidelines provide a comprehensive resource for clinicians and include recommendations on topics ranging from screening and diagnosis to the management of local or locoregional and metastatic disease. <Read More>

    Considerations for the Diagnostic Work-Up of Breast Implant–Associated Lymphoma – July 2, 2020 – Flow cytometry (FC) can efficiently diagnose breast implant–associated anaplastic large-cell lymphoma (BIA-ALCL), and may differentiate it from other CD30-positive lymphomas, according to a letter to the editor of the Journal of Clinical Oncology. <Read More> 

    Survey: Rheumatologists Still Reluctant to Switch Patients to Biosimilars – July 2, 2020 – Cardinal Health recently conducted a survey of more than 100 rheumatologists asking their feelings about biosimilars, and the findings revealed that the majority of them were familiar with and comfortable prescribing biosimilars…However, a majority of rheumatologists surveyed still indicated they are reluctant to switch from reference products to biosimilars, at least partly because they don’t believe there is enough of a cost savings. In fact, only 11% of the rheumatologists surveyed said they were likely to prescribe a biosimilar to a patient who is having success on a reference product today — and the lack of a significant cost benefit appears to be a key reason. <Read More>

    Federal Appeals Court Blocks Launch Of Biosimilar Erelzi – July 2, 2020 – A federal appeals court upheld two patents for Amgen’s Enbrel (etanercept). Sandoz had petitioned the court to void the patents, and applied to market Erelzi, a biosimilar version of Enbrel. Enbrel is a biologic that treats five inflammatory conditions. Last year, its global sales were $9.6 billion, with the U.S. accounting for over half – approximately $5 billion. <Read More>

    Middle-Aged Women Often Develop Hypertension – July 2, 2020 – Hypertension (HTN) is implicated in about 20% of deaths among American women, and women are more likely to develop HTN than men. Women are also more likely to develop related pathophysiologic damage, such as chronic kidney disease, diabetes, diastolic dysfunction, heart failure, increased arterial stiffness, and left ventricular hypertrophy. For this reason, controlling HTN in women is critical. Lowering blood pressure (BP) reduces adverse cardiovascular outcomes. <Read More>

    An Algorithm Can Help Select the Best Psychological Treatment – July 2, 2020 – Clinical guidelines for the treatment of depression and anxiety problems recommend evidence-based psychological interventions organized in a stepped care model, where patients initially access low-intensity self-help interventions guided by qualified practitioners and later have the option to access high-intensity psychological therapies if their symptoms persist…Using the regression weights for each of these features, the authors developed the Leeds Risk Index (LRI), a simple tool that enables clinicians to profile patients into subgroups with low,moderate, or high risk of poor response to psychological treatment. <Read More>

    New Guideline for COPD Provides Updates on Medication Management – July 2, 2020 – The American Thoracic Society (ATS) released a clinical practice guideline on the pharmacologic management of COPD. This guidance, in conjunction with the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines, is useful in helping pharmacists manage patients with COPD. “Both the ATS and GOLD guidelines are evidence based, but the ATS guidelines are much more concise,” said Suzanne G. Bollmeier, PharmD, FCCP, BCPS, AE-C, professor of pharmacy practice at the St. Louis College of Pharmacy. <Read More> 

    Study Finds Flaws in Widely-Used Pricing Model for Generic Drugs – July 2, 2020 – A new US industry analysis finds evidence that a longstanding price benchmark, Average Wholesale Price (AWP), does not provide an accurate representation of retail generic drug prices. In the USA, AWP is used by traditional pharmacy benefit managers (PBMs) to set reimbursement rates for pharmacies on behalf of US health insurers and plan sponsors. The analysis concludes that, while the actual acquisition price of generic drugs purchased by retail pharmacies has decreased over the past six years, the index by which discounts for these drugs are established has increased. <Read More> 

    The Pharmacy HIT Collaborative Requests Public Comments on Updated Pharmacy Value Sets – July 2, 2020 – The Pharmacy Health Information Technology (HIT) Collaborative has revised a draft version of pharmacy value sets and has requested comments from stakeholders, according to a press release. The Pharmacy HIT Collaborative is a coalition of 9 pharmacy associations and other stakeholders, and they support pharmacists in matters related to health information technology. Previously, comments had been collected in a PDF document. However, they are now accessible through an online database. <Read More> 

    NACDS: Electronic Prescriptions for Controlled Substances Should be Mandatory – July 1, 2020 – NACDS is urging the Drug Enforcement Administration (DEA) to make electronic prescriptions for controlled substances (EPCS) mandatory. In comments on the reopening of the Interim Final Rule (IFR) for EPCS, NACDS described the significant benefits associated with EPCS, and offered recommendations on how best to achieve these benefits. “For more than 20 years NACDS has collaborated with DEA on the development and implementation of policies and standards for EPCS. We remain committed to the use of electronic prescriptions for all medications, especially controlled substances,” NACDS wrote. <Read More>

    Can Progression of Parkinson Disease Be Slowed? – July 1, 2020 – Deep brain stimulation (DBS) implanted in early-stage Parkinson disease (PD) was found to decrease the risk of disease progression. If findings are replicated in a larger trial recently approved by the FDA, DBS would be the first therapy proven to slow the progression of any element in PD. <Read More> 

    New Drug Launches Stalled by COVID-19 Pandemic – July 1, 2020 – The U.S. Food and Drug Administration has approved more than 30 new drugs since January. So far, five medicines have seen their commercial launches delayed by manufacturers until later in the year or 2021 because of the COVID-19 pandemic. <Read More> 

    Pfizer and Biontech Announce Early Positive Data From an Ongoing Phase 1/2 Study ff MRNA-Based Vaccine Candidate Against SARS-COV-2 – July 1, 2020 – Pfizer Inc. and BioNTech SE announced preliminary data from the most advanced of four investigational vaccine candidates from their BNT162 mRNA-based vaccine program, Project Lightspeed, against SARS-CoV-2, the virus causing the current global pandemic. The BNT162 program is evaluating at least four experimental vaccines, each of which represents a unique combination of mRNA format and target antigen. The manuscript describing the preliminary clinical data for the nucleoside-modified messenger RNA (modRNA) candidate, BNT162b1, which encodes an optimized SARS-CoV-2 receptor binding domain (RBD) antigen, is available on an online preprint server at https://www.medrxiv.org/content/10.1101/2020.06.30.20142570v1 and is concurrently undergoing scientific peer-review for potential publication. Overall, the preliminary data demonstrated that BNT162b1 could be administered in a dose that was well tolerated and generated dose dependent immunogenicity, as measured by RBD-binding IgG concentrations and SARS-CoV-2 neutralizing antibody titers. <Read More>

    Faster Cath Lab Activation Times Make a Big Impact on Patient Care – July 1, 2020 – Rapid reperfusion is linked to improved survival for STEMI patients, a point confirmed again and again by numerous studies and clinical guidelines. Delayed care is still prevalent, however, especially when the patient presents at a facility where percutaneous coronary intervention (PCI) is unavailable and transportation is required. The authors of a new study in Circulation: Cardiovascular Quality and Outcomes focused on the importance of a fast cath lab activation times, noting that a time within 20 minutes was associated with PCI being completed within the national goal of 120 minutes or less. <Read More>

    Statins May Prevent Heart Attacks and Strokes but May Not Prolong Life Free of Disability – July 1, 2020 – A new observational study shows the first-line cholesterol-lowering drugs known as statins are associated with fewer heart attacks and strokes, but not associated with a prolonged life free of physical disability and dementia in healthy elderly people. <Read More> 

    Broad-Spectrum Antibiotics Are Overused in Treatment of CA-cIAI – July 1, 2020 – Broad-spectrum antibiotics are overused in the treatment of community-acquired complicated intra-abdominal infection (CA-cIAI), according to a new study. The retrospective, observational study, published in Open Forum Infectious Diseases, aimed to determine treatment patterns and examine compliance with guidelines discouraging use of anti-pseudomonal β-lactams and fluoroquinolones for CA-cIAI. <Read More> 

    New Guidelines Issued for Patients with Moderate-To-Severe Ulcerative Colitis – July 1, 2020 – The American Gastroenterological Association (AGA) has produced new guidelines to support the management of patients with moderate to severe ulcerative colitis (UC). The guideline sought to address the medical management of adult outpatients as well as those who are hospitalised with the condition. There are 11 recommendations and for each one there is an estimate of the strength of the recommendation (that is, strong, conditional or no recommendation) and the quality of the associated evidence (for example, high/moderate/low/very low/or evidence gap). <Read More> 

    Updated Transplant Guidelines Allow for More Organ Donations – July 1, 2020 – On June 25, federal government revised guidelines for organ transplants that will likely result in more organ donations, according to a press release from the Department of Health and Human Services (HHS) and the Public Health Service, which issued the guidance. Notably, the update includes new criteria for identifying donors with potentially undetected HIV and hepatitis B and C viruses (HBV and HCV). Thanks in part to advances in testing and treatment, more organs can now be accepted from people who would have been classified as an increased risk donor (IRD). <Read More> 

    Vizient Pharmacy Network Committee Study Published in JAMA Finds Patients with Presumed Penicillin Allergy Given Less Effective, More Harmful Antibiotics – July 1, 2020 – A study facilitated by Vizient, Inc. and recently published in the Journal of American Medical Association Internal Medicine yielded new insights about patients with presumed penicillin allergies. The study, led by researchers at Massachusetts General Hospital, found that physicians unnecessarily prescribe inferior antibiotic alternatives to patients with documented penicillin allergies. Because 90% of documented penicillin allergies are unconfirmed, researchers conclude that some substitutions are unnecessary, less effective and can even be harmful. <Read More>

    Ending Diabetes Treatment for Hospice Patients May Improve Quality of Life – June 30, 2020 – Older adults who suffer from a life-limiting illness or advanced dementia may benefit from cessation of diabetes treatment as they near their final days, new research has found. Prior research on appropriate levels of diabetes is scarce, according to the study’s authors. But their conclusions suggest that continuing diabetes treatment at the end of life could present fall risks, loss of consciousness or adverse drug events. The research was published in the Journal of the American Geriatrics Society. <Read More> 

    Commonly Prescribed Drug Found to Be Ineffective in Slowing Kidney Disease – June 30, 2020 – A drug commonly prescribed for people with kidney disease doesn’t prevent decline in kidney function. That’s the conclusion from a clinical trial in Australia that found the drug allopurinol (Zyloprim, Aloprim) doesn’t prevent worsening of kidney disease. “We compared the use of allopurinol to a placebo and found, to our surprise, that it made no difference to the rate of kidney function decline,” David Johnson, PhD, researcher on the study and medical director at the Queensland Kidney Transplant Service, said in a press release. <Read More> 

    FDA Sets Bar for COVID-19 Vaccine Approval at 50 Percent Effectiveness – June 30, 2020 – While the U.S. and the world have largely fast-tracked efforts to develop a vaccine against COVID-19, experts in the field of immunology and virology have expressed concerns about the speed with which those efforts are moving. The U.S. Food and Drug Administration (FDA) issued guidelines for where it will set the bar for approval of a vaccine, and that bar may not be as high as many would like. <Read More> 

    CDC: Partnerships With Pharmacists Expand Diabetes Prevention Efforts – June 30, 2020 – The CDC partnered with pharmacy stakeholders to develop resources and promotional materials tailored to the needs and values of pharmacists to expand the National Diabetes Prevention Program (National DPP) in pharmacies across the country…Pharmacies and pharmacists are key partners in the program, since they are uniquely positioned to care for underserved populations who are also at increased risk for prediabetes, and developing type 2 diabetes, according to the CDC. One in 3 adults in the United States has prediabetes, which leads not only to type 2 diabetes, but also heart disease and stroke. <Read More> 

    RXVIP Concierge Defends the Critical Role of Pharmacists as Front-Line Healthcare Providers – June 30, 2020 – The services offered by RXVIP Concierge highlight the critical role that pharmacists play as front-line healthcare providers. In the company’s concierge approach to patient engagement, PharmDs and PharmD interns perform thorough and accurate risk assessments of patients’ health, allowing them to make cost-saving and in some cases life-saving recommendations to their physician. This distinctly modern platform also supports the ongoing care coordination to closely monitor the well-being of patients. Additionally, the PharmD helps Physicians assess patients virtually via telemedicine, thereby protecting vulnerable patients who should not be coming into the office. <Read More> 

    Air Pollution a Key Contributor to Cardiovascular Disease Regardless of Country Income – June 30, 2020 – A recent international study published in The Lancet Planetary Health showed that long-term exposure to fine particulate outdoor air pollution is a key contributor to cardiovascular disease and death throughout the world, regardless of the income bracket of the various countries. Furthermore, the study showed that even small reductions in the level of air pollution could result in reduced mortality. <Read More> 

    Pharmacy Schools Are Important for MTM Services – June 30, 2020 – Pharmacy students can play an integral role in medication therapy management (MTM) services. Teaching students the core concepts through their didactic training can help prepare them for clinical rotations. As part of its standards, the Accreditation Council for Pharmacy Education for the PharmD program emphasizes the importance of pharmacy students possessing MTM competence and knowledge to be successful on clinical rotations.1 Pharmacy students can also be integrated into MTM services through telehealth during the coronavirus disease 2019 (COVID-19) pandemic. <Read More>

    340B in the News

    Senate Bill Aims to Preserve 340B Eligibility for Hospitals Affected by COVID-19 Pandemic – July 6, 2020 – A group of bipartisan senators introduced legislation to ensure that a hospital doesn’t fall out of the 340B drug discount program due to a rapid change in patient volume sparked by COVID-19. The bill introduced last week comes as hospitals continue to grapple with a financial crisis sparked by the pandemic. It also centers on a controversial program that the Trump administration has sought to cut by more than a third. <Read More> 

    Community Practice Mergers and Acquisitions Rise Steeply Over 2 Years, COA Report Reveals – July 2, 2020 – The 2020 Oncology Alliance (COA) Practice Impact Report, released on April 24 during the Community Oncology Conference, showed a significant increase in community oncology practices merging and/or being acquired by nonhospital practices or corporate entities…The number of practices merging with or being acquired by another community oncology practice and/or corporate entity rose by 20.8% compared with the number in the 2018 COA Practice Impact Report. This year’s authors speculate that the change is because practices want protection from hospital merger pressures. These practices received financial incentives through the 340B Drug Discount Program and higher payments to hospitals for cancer care services, also the reason for a 9.7% increase in practices acquired by hospitals from 2018 to 2020. <Read More>

    APIs And Fixing Drug Discounting’s $8 Billion-A-Year Problem – June 29, 2020 – Call it healthcare’s $8.5 billion problem. That’s how much is lost by U.S. drug manufacturers amid a cumbersome pricing and discounting system that is anything but transparent. As Jeremy Docken, CEO and founder of Kalderos, told Karen Webster, that waste is due in part due to the fact that there is so much money changing hands — $166 billion in drug discounts alone — across patients, providers, payers and programs… At present, the company supports compliance efforts across several healthcare programs, including Medicaid and the Medicaid Drug Rebate Program (MDRP), in addition to Medicare Part D and the 340B Drug Pricing Program (340B Program). <Read More>